By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tesaro, Inc. 

309 Waverley Oaks Road
Suite #101
Waltham  Massachusetts  02452  U.S.A.
Phone: 339-970-0900 Fax: n/a



Company News
Tesaro, Inc. (TSRO) Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015 1/12/2015 8:03:43 AM
Tesaro, Inc. (TSRO) And AnaptysBio, Inc. Expand Immuno-Oncology Collaboration To Include Novel Bispecific Antibody Candidate 12/2/2014 11:51:12 AM
Tesaro, Inc. (TSRO) To Present At The Nasdaq 31st Investor Program 12/1/2014 4:17:39 PM
Tesaro, Inc. (TSRO) To Present At The 2014 Deutsche Bank (DB) BioFEST 11/26/2014 11:44:26 AM
Tesaro, Inc. (TSRO) And Myriad Genetics, Inc. (MYGN) Announce Companion Diagnostics Collaboration 11/20/2014 10:44:14 AM
Tesaro, Inc. (TSRO) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 11/12/2014 10:24:28 AM
Tesaro, Inc. (TSRO) Announces Third-Quarter 2014 Operating Results 11/6/2014 8:08:58 AM
Tesaro, Inc. (TSRO) To Announce Third-Quarter 2014 Financial Results On November 5, 2014 10/23/2014 7:33:28 AM
Tesaro, Inc. (TSRO) Announces Closing Of $201.25 Million Public Offering Of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise Of The Underwriters' Option To Purchase Additional Notes 9/29/2014 11:55:48 AM
Tesaro, Inc. (TSRO) Announces Pricing Of $175 Million Of 3.00% Convertible Senior Notes Due 2021 9/24/2014 7:22:15 AM